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Abstract
Microarray analysis of the multiple myeloma (MM) miRNome has unraveled the differential expression of miRNAs in
cytogenetic subgroups, their involvement in the tumor biology and their effectiveness in prognostic models. Herein,
the small RNA transcriptional landscape in MM has been investigated exploiting the possibilities offered by small RNA-
seq, including accurate quantiﬁcation of known mature species, discovery and characterization of isomiRs, and miRNA-
offset RNAs (moRNAs). Matched small RNA-seq and miRNA GeneChip® microarray expression proﬁles were obtained in
a representative panel of 30 primary MM tumors, fully characterized for genomic aberrations and mutations. RNA-seq
and microarray gave concordant estimations of known species. Enhanced analysis of RNA-seq data with the
miR&moRe pipeline led to the characterization of 655 known and 17 new mature miRNAs and of 74 moRNAs
expressed in the considered cohort, 5 of which (moR-150-3p, moR-24-2-5p, moR-421-5p, moR-21-5p, and moR-6724-
5p) at high level. Ectopic expression of miR-135a-3p in t(4;14) patients, upregulation of moR-150-3p and moR-21-5p in
t(14;16)/t(14;20) samples, and of moR-6724-1-5p in patients overexpressing CCND1 were uncovered and validated by
qRT-PCR. Overall, RNA-seq offered a more complete overview of small non-coding RNA in MM tumors, indicating
speciﬁc moRNAs that demand further investigations to explore their role in MM biology.
Introduction
Many studies highlighted the relevant role of micro-
RNAs (miRNAs) in the pathology of multiple myeloma
(MM)1. Microarray and quantitative real-time PCR (qRT-
PCR) analyses of the miRNome of plasma cells (PCs) from
primary MM tumors have unraveled the differential
expression of miRNAs and miRNA clusters in speciﬁc
molecular subgroups, exemplarily the marked upregula-
tion of the miR-99b/let-7e/miR-125a-5p cluster in t
(4;14)2–4. We and others have demonstrated the effec-
tiveness of miRNA expression to predict outcome and
proﬁciently integrate ISS-based models5,6. The prognostic
role of miRNAs in the form of circulating exosomal
species is also emerging7,8. Recently, taking advantage of
proprietary and publicly available transcriptional data,
including paired miRNA and gene expression proﬁles of
primary tumors, we provided a global and integrated view
of miRNA transcriptional relationships in MM9,10.
However, to date, the investigation of miRNA expres-
sion in MM has been limited to microarray or PCR
approaches. Albeit the cohorts and the number of inves-
tigated RNAs became increasingly extensive, the study of
small RNA has still not exploited all the possibilities
offered by next-generation sequencing. These include, but
are not limited to, (i) improved detection of low-expressed
mature species, (ii) accurate quantiﬁcation of isomiRs11,
and (iii) comprehensive investigation of miRNA-offset
RNAs (moRNAs)12,13. Recent studies have in fact
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demonstrated that almost half of the identiﬁed miRNA
genes encode up to four stable small RNA species: two
miRNAs and two moRNAs, which are likely to be pro-
duced by the RNAse III-like processing of pre-miRNA
hairpins and stem from the sequences immediately adja-
cent to the two mature −5p and −3p miRNAs13–15. Like
miRNAs, moRNAs are ~20 nt long and are regulated at
different developmental stages12,16. Langenberger et al.
ﬁrstly reported that many human pre-miRNAs are pro-
cessed to produce moRNAs in a systematic way. We and
others have uncovered moRNA expression in pigs, among
which it is worth reporting that of moR-21-5p, stemming
from the processing of extended precursor hairpins17,18.
Very recently, the transcriptional pattern of short non-
coding RNAs, including moRNAs, has been characterized
by deep sequencing in normal and neoplastic CD34+
cells, evidencing the speciﬁc and miRNA-independent
modulation of moRNAs derived by non-canonically pro-
cessed hairpins19. Several evidence, ranging from obser-
vational studies that reported high-sequence conservation
between human and other species20 to recent functional
investigations in vitro21,22, concordantly indicate that
moRNAs could be functional RNAs. Based on these
premises, the aim of the present work is to provide a more
complete view of miRNA transcriptional landscape in
MM, through RNA-sequencing (RNA-seq) analysis in a
panel of primary tumors representative of the major
molecular types.
Methods
Patients
Bone marrow aspirates were obtained during standard
diagnostic procedures from 30 MM at diagnosis. PCs were
puriﬁed using CD138 immunomagnetic microbeads and
the purity of the positively selected PCs (>90%) was
assessed using ﬂow cytometry as previously reported23,24.
All PC dyscrasia cases were investigated by ﬂuorescence
in-situ hybridization for the major immunoglobulin heavy
chain locus (IGH@) translocations and genetic lesions, and
MM patients were stratiﬁed according to molecular
prognostic stratiﬁcation25 (Supplementary Table 1).
Mutational status of BRAF, NRAS and KRAS, DIS3,
FAM46C, and TP53 genes were assessed by targeted
sequencing from genomic DNA by the Genome Sequencer
Junior instrument (Roche-454 Life Sciences, Penzberg,
Germany) as previously described26–28 (Supplementary
Table 1). Written informed consent was obtained from all
patients in accordance with the Declaration of Helsinki.
The study was approved by the Ethical Committee of the
University of Milan (N° 24/15, May 06 2015).
Small RNA-sequencing
RNA-seq data were generated at the next-generation
sequencing service of Parco Tecnologico Padano (Lodi,
Italy). Small RNA cDNA libraries (for transcripts < 30 nt)
were built following standard Illumina Truseq® Small
RNA protocol, starting from 2 μg of total RNA for each
sample. BluePippin system was used for fragments selec-
tion within the range of 145–160 bp. RNA-seq was
performed on Illumina HiSeq platform. A 50-cycle
single-reads sequencing was run to generate the tags
corresponding to small-RNAs.
Small RNA detection, discovery, and quantiﬁcation
Small RNA data analysis was conducted with an
extended version of the miR&moRe pipeline (Supple-
mentary Figure 1)29 (detailed procedure as described in
Gaffo et al.18). Brieﬂy, the ﬁrst step was reads pre-
processing for adapter removal, namely discarding
“adapter-only” or unclipped reads. Then, reads with a
length range between 15 and 30 nt (which encompassed
the length range of human annotated miRNAs in miR-
Base and possible moRNAs and/or shorter/longer iso-
miRs) were considered for the further quality-based
ﬁltering, which kept reads with mean base quality higher
than 30 and at most 2 nucleotides with quality under 20.
Reads belonging to unique sequences with less than 10
reads counts each were discarded to remove ground
noise. Then, ﬁltered reads have been mapped, using
Bowtie v1.1.030, both to the GRCh38 genome assembly
and the known hairpins sequences (miRBase version
2131,32) extended in either directions by additional
30 bp. Reads mapping to more than ﬁve different loci on
the genome out of miRBase annotated hairpins have
been discarded to reduce noise.
The following steps implemented in miR&moRe pipe-
line are then performed: (i) quantiﬁcation of known
miRNAs and (ii) isomiR characterization; in parallel, (iii)
discovery of sister miRNAs and (iv) possible miRNA-
offset RNAs produced from the considered hairpin pre-
cursors18. Known mature miRNAs are ﬁrst recognized,
then for hairpins containing only one annotated mature
miRNA, RNAfold is used to deﬁne the most probable
hairpin structure and the region complementary to
the known miRNA, thus identifying the most probable
miRNA duplex, reaching the identiﬁcation of sister
miRNAs. Expressed small-RNAs with the central
nucleotide localized upstream of the region covered by the
5′ mature miRNA or downstream of the region covered by
the 3′ mature miRNA, were considered 5′-moRNAs and
3′-moRNAs, respectively. The pipeline outputs known
miRNA read counts, detects sequence and quantiﬁcation
data for new miRNAs and moRNAs, and lists of variants
(isomiRs) for all the small-RNAs found in each sample,
with quantiﬁcation of each isomiRs. Then, the merged
matrix of raw read counts in all considered samples
underwent normalization using the R/Bioconductor
package DESeq.
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Cluster analysis of expression proﬁles was performed
using standard hclust methods in R. Differential expres-
sion tests were conducted using the Bioconductor Pack-
age edgeR33; negative binomial generalized log-linear
model was ﬁtted to the reads count for each short RNA
and then exact test p-values were calculated for every
contrast of interest (each group, individually, vs the oth-
ers, as a whole). Multiple test correction was performed
according to Benjamini–Hochberg method.
MiRNA array expression proﬁling
Total RNA samples from the same 30 MM patients
were proﬁled on the GeneChip® Human miRNA v3.0
array (Affymetrix, Santa Clara, CA, USA). Normalized
expression data of 1768 human mature miRNAs were
extracted using RMA normalization3 and custom anno-
tations based on miRBase release 21 (http://brainarray.
mbni.med.umich.edu/Brainarray/Database/CustomCDF/
21.0.0/mirbasef.asp).
moRNA-target prediction
The identiﬁcation of putative moRNA binding sites and
corresponding heteroduplexes on mRNA target sequen-
ces was run using the downloadable dynamic tool of
RNA2234 prediction algorithm (https://cm.jefferson.edu/
rna22/), under customized parameters (i.e., default setting
on sensitivity/speciﬁcity ratio, 7 nucleotides on seed
region without any unpaired base allowed, one G:U
wobble accepted, 14 as minimum required number of
base-pairs between the moRNA and the target, −20 kcal/
mol maximum allowed free energy). A list of 764 genes
mapped to GRCh38 primary assembly and associated with
MM (from now on, referred as “MM-genes”) was down-
loaded from NCBI database (https://www.ncbi.nlm.nih.
gov/gene) and a total of 17,356 fasta-formatted sequences
for all the MM-genes annotated trasncripts was used for
the downstream analysis.
Quantitative real-time PCR (qRT-PCR) validation
Selected mature miRNAs underwent qRT-PCR valida-
tion using custom TaqMan™ small RNA assays (Applied
Biosystems) in accordance with the manufacturer’s pro-
tocol. Speciﬁcally, commercial assay was purchased for
miR-135a-5p, whereas made-to-order TaqMan™ assays
were designed on the most represented sequences for
moR-21-5p (CTCCATGGCTGTACCACCTTGTCGG),
moR-150-3p (GGGACCTGGGGACCCCGGCACCGG-
CAGG), and moR-6724-1-5p (TGTGGGGGAGAGGC
TGTCGCTGCGCTTCTGGGCC). All the assays were
normalized on the basis of the RNU48 TaqMan™ miRNA
Assays-Control, used as housekeeping in view of its
abundance and very low variability within PCs. Relative
miRNA expression was quantiﬁed using the 2−ΔCt
method (Applied Biosystems, User Bulletin No.2). As a
normal counterpart for moRNA expression evaluation, a
representative panel of normal hemopoietic tissue sam-
ples available in our Institution biobank were used: 4 PCs,
5 germinal center B-cells, 5 naive B-cells, and 5 memory
B-cells samples from tonsil avulsion during standard
surgery, together with 4 mononucleated cells samples
derived from peripheral blood (PBMC) of healthy donors,
obtained as previously described35.
Results
To provide an exhaustive view of the small-RNAs in
MM, combined small RNA-seq (sRNA-seq) data and
array expression proﬁles of a cohort of 30 primary MM
tumors were considered. The selected MM cases (Sup-
plementary Table 1) are representative of common
molecular features in MM: IGH translocation with
prognostic relevance (4p16, 7 cases; MAF, 4 cases; and
11q13 groups, 8 cases)6; 16 cases had 1q gain, 18 del(13)
and 3 del(17); 8 cases were hyperdiploid (the number of
cases with each molecular feature was chosen to optimize
discovery power and costs).
Deep characterization of small RNA in myeloma
Small RNA-seq data were generated in a cohort of 30
MM samples at diagnosis. Overall, 18.7 million average
sRNA-seq reads per sample were obtained and 90.3% on
average passed ﬁltering steps (Supplementary Figure 2).
Analysis of RNA-seq data by miR&moRe led to the
quantiﬁcation and molecular characterization of known
miRNA species, integrated with the deﬁnition of isomiR
sequences, and to the de novo identiﬁcation of miRNA
and moRNAs.
Known and new miRNAs
A total of 672 expressed miRNAs were detected in at
least one sample, including 655 known and 17 newly
annotated miRNAs.
Notably, only 51 known miRNAs (i.e. <2% of the 2813
annotated mature miRNAs in miRbase v21) represented
up to 95% of the observed expression signals in MM, with
a few of them very highly expressed: namely, the sum of
the reads of only four mature miRNAs (miR-148a-3p,
miR-181a-5p, miR-26a-5p, let-7a-5p) represented up to
50% of the expressed transcripts (Fig. 1a). Our analysis led
also to the identiﬁcation of 17 still undescribed, mature
miRNAs originating from the annotated stem-loops.
These new species were in general weakly expressed, but 6
new miRNAs had average expression over the median of
all detected sRNAs (Supplementary Table 2).
The signal of each miRNA was calculated as the sum of
the contribution of “exact” (i.e., with sequence and
boundaries according to miRbase annotation) together
with isomiR variants, namely those exceeding the known
miRNA boundaries for at most three nucleotides, likely
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resulting from alternative Dicer processing or post-
processing modiﬁcations as described12, or showing mis-
matches (at most one anywhere or two in the 3′ half of the
sequence), compatible with possible SNPs or edited
bases18. Overall, exact variants contributed only to 40.7%
of total normalized read counts. Of the remaining 59.3%,
the majority of isomiRs (76.4%) was represented by
shorter or longer mature species without mismatches.
Importantly, as previously reported, not all the miRNA
species had the exact sequence (i.e., the mature miRNA
annotated in miRbase) represented among detected iso-
miRs. In other words, the exact sequence may not
necessarily represent the most abundant isomiR, as well as
in some extreme cases “non-exact” isomiR contribution
may represent up to the whole signal of the mature
miRNA. Figure 1b reports the exemplar case of miR-150,
where the −3p miRNA is entirely represented by mis-
matched or shorter/longer sequences.
Matched miRNA expression proﬁles obtained in the
same sample set with RNA-seq and with microarray
technologies were compared. Very good concordance is
observed for higher signals, despite an apparently quite
poor correlation (r= 0.24) when all the expressed species
were considered. Both the scatter plot (Supplementary
Figure 3A) and the array expression-based stratiﬁcation of
the correlation coefﬁcients of each transcript (Supple-
mentary Figure 3B) clearly indicated that any dissimilarity
depended mostly on array expression signals just above
the noise level.
moRNAs
In the proﬁled series of 30 MM cases, 74 moRNAs were
identiﬁed. Notably, several moRNAs had high and group-
speciﬁc expression, as detailed below.
Overall, moRNAs represent around 10% of expressed
sRNAs species and show prevalently a low abundance,
Fig. 1 MiRNA expression in MM according to small RNA-seq: a Cumulative expression of sRNAs, ordered by expression level; b percentage of different
isomiR species for miR-150-5p and -3p
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accounting globally for <1% of detected sRNA expression,
concordantly with previously reported evidence21.
Nevertheless, 25 moRNAs had expression over the med-
ian of the sums of reads across all the samples, and 5 of
them in the upper quartile of most expressed sRNAs
(Table 1).
sRNA-speciﬁc expression characterizes MM molecular
subgroups
Differential expression analysis of expression proﬁles
based on RNA-seq data identiﬁed miRNAs and moRNAs
with expression speciﬁc/variable in each the 4p16, MAF,
11q13, and CCND1+ group.
The analysis of differentially expressed miRNA between
MM prognostic subgroups indicated good level of overall
concordance between the results obtained using micro-
array and RNA-seq approaches: more than 90% of the
differentially expressed miRNAs resulting from micro-
array analysis were concordantly detected by RNA-seq.
Conversely, as expected, only 80% of differentially
expressed transcripts detected by RNA-seq were also
identiﬁed by microarray analysis, in all likelihood in virtue
of lower noise and the detection unconstrained to pre-
determined sequences offered by RNA-seq (Supplemen-
tary Table 3).
Figure 2 shows the differentially expressed transcripts
whose sum of reads exceeded the third quartile of all the
sums of reads. Marked upregulation of the well-described
miR-99b/let-7e/miR-125a-5p cluster was detected in t
(4;14) patients by RNA-seq and arrays. Of interest,
abnormal and speciﬁc expression of miR-135a-5p in t
(4;14) patients was unraveled by RNA-seq, most likely
overcoming hybridization biases due to sequence simi-
larity within miR-135 family that might affect microarray
investigation and thus previous reports3.
MiR-135a-3p, originating from the same stem loop of
miR-135a-5p but expressed at relatively weaker levels,
showed slight but anyway speciﬁc upregulation in t(4;14)
patients, in line with the notion of imbalance in the
abundance representation of sister mature species.
Among the highly expressed offset sRNAs, three were
differentially expressed within the molecular subgroups:
moR-150-3p and moR-21-5p in t(14;16)/t(14;20) samples,
and moR-6724-1-5p in patients with high CCND1 levels
(Fig. 3, all P < 1 × 10−3). qRT-PCR analysis of the
expression level of miR-135-5p, moR-150-3p, moR-21-5p,
and moR-6724-1-5p in a representative panel of cases for
which RNA material was available and representing all the
considered MM subgroups, conﬁrmed the new ﬁndings
and supported data reliability. Very highly signiﬁcant
correlations were found for the species analyzed (Fig. 4).
Only for moR-6724-1-5p marginal signiﬁcance was
reached according to PCR estimations: in this case, we
cannot exclude that discrepancies might be due to
sequence length, in that the extended hairpin sequence,
which possibly leads to moR-6724, could fold in a quite
stable, non-conventional, hairpin conﬁguration according
to (predictions obtained by RNAfold (Supplementary
Figure 4)).
The expression levels of the newly identiﬁed moRNAs
were analyzed in a set of normal B-cell and PC popula-
tions from healthy donors. Notably, moR-6724-1-5p
showed signiﬁcantly high expression in non-pathological
B- and PCs (Supplementary Figure 5), which prompts to
suggest that its down-modulation could be somehow
involved in the tumor cell development processes. A
similar trend could be observed in moR-150 and moR-21
expression, where median levels in MM were overall
lower, albeit not signiﬁcantly, than in normal samples.
In most cases, signiﬁcant direct correlation was detected
between the expression proﬁles of the most abundant
moRNA and the miRNA derived from the same hairpin
(Fig. 5), albeit with variable correlation strengths and
ratios between the absolute levels of moRNA and its
Table 1 Five moRNAs presenting highest expression across the dataset
moRNA Precursor miRNA Sequence Rank
moR-150-3p mir-150 GGGACCTGGGGACCCCGGCACCGGCAGG 148
moR-24-2-5p mir-24-2 TGGCCTCCCTGGGCTCTGCCTCC 149
moR-421-5p mir-421 TAATCCGGTGCACATTGTAGG 163
moR-21-5p mir-21 CTCCATGGCTGTACCACCTTGTCGG 164
moR-6724-5p mir-6724-1 TGTGGGGGAGAGGCTGTCGCTGCGCTTCTGGGCC 191
mir-6724-2
mir-6724-3
mir-6724-4
For each moRNA, the precursor miRNAs, the sequence and their ranking among the 768 sRNAs detected and ordered according to the sum of reads across the 30
myeloma samples are indicated
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cognate miRNA. MoR-150-3p and moR-6724-5p proﬁles
were highly correlated with the corresponding miRNAs,
moR-6724-5p was more expressed than miR-6724-5p in a
subset of samples. MoR-21-5p was considerably more
weekly expressed than miR-21-5p and, notably, the
moRNA was not expressed in a subset of samples pre-
senting with high miR-21-5p levels. More divergent
expression proﬁles were observed for moR-421-5p and
miR-421-5p: both sRNAs showed variable expression in
the considered set of cases, and none of them was dif-
ferentially expressed in molecular subgroups.
Prediction of putative moRNA transcriptional target in MM
To investigate the possible involvement of novel
moRNA species in the regulation of MM transcriptional
milieu, we ﬁrst used in silico approach to extract a list of
putative target transcripts based on the supposed high-
afﬁnity binding site. Although, to date, a clear
demonstration has still not been provided, we might bona
ﬁde presume that the moRNA may act as conventional
mature miRNAs to regulate possible targets target tran-
scripts. Almost 800 coding and non-coding genes, which
have been somehow related to MM to date according to
the curated NCBI Gene annotation database, were con-
sidered to predict possible targets of the six most highly
expressed moRNAs. The robust RNA22 target-prediction
algorithm34 was used to extract and score predicted
moRNA-target regulatory relationships (Supplementary
Data). Amongst predicted targeting relationships (Sup-
plementary Table 4), those involving moR-150-3p with
RUNX1 and moR-6724-1-5p with TSC2 were of particular
interest.
Discussion
To date, the detection of miRNA transcripts in mye-
loma has been mainly conﬁned to PCR- or array-based
Fig. 2 MiRNAs and moRNAs differentially expressed between MM prognostic subgroups. Histograms of relative fold changes of the differentially
expressed miRNA, among those in the upper quartile of average expression, in a 11q13, b CCND1+, c 4p16, and d MAF genes translocated (MAFtrx)
patients. Green indicates downregulation and red indicates upregulation (moRNA is shown in dark red)
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approaches. The high RNA-seq discovery power well
balances the cost per sample, which sensibly decreased in
the last years and is largely justiﬁed by the advantages of
de novo investigations. Herein, we analyzed by RNA-seq a
representative cohort of myeloma samples that had been
previously characterized for molecular features and pro-
ﬁled by expression arrays, with the ultimate purpose of
unraveling previously undescribed short sRNAs with
potential implication in myeloma biology.
The ﬁrst relevant ﬁnding concerned the relative
abundance of known miRNA transcripts. Surprisingly,
only four mature species seized up to about 50% of the
reads, namely of the detected transcripts (additional six
miRNAs increased the total capture level to 70%). Such
miRNAs are commonly expressed at high level in several
cell types, most likely contributing to physiological
processes, and their overexpression is preferably asso-
ciated with tumor suppressive activity. In PCs, miR-181a
was described more expressed in MM than in healthy
donors36. In our MM series, they were ubiquitously
expressed independent of molecular subtypes. Circu-
lating let-7a, miR-26a, and miR-181a were described as
expressed at aberrant levels in tumor plasma or
serum37,38.
Considering the ﬁnite set of miRNA contained in the
arrays, RNA-seq data have reinforced previous ﬁndings.
Moreover, RNA-seq data extended and completed the
picture, surpassing the limitations of microarray analysis,
affected by noise for the low-signal species and providing
new discoveries. A marked upregulation of miR-135a-5p
emerged in t(4;14) patients, not detected by microarray
analysis neither in this nor in previous studies. Possibly,
issues in array design and low speciﬁcity of array probes
can explain this missing ﬁnding, since upregulation of
miR-135a-5p in t(4;14) has been strongly conﬁrmed by
qRT-PCR in an extended cohort.
Abnormal expression of miR-135a has been docu-
mented in several cancer types, but the most striking
evidence of the involvement of miR-135a in B-cell tumors
was reported in Hodgkin’s lymphoma tumors, where
Fig. 3 Expression of the most abundant moRNA in different molecular groups of MM patients, stratiﬁed on the basis of translocations/CCND1
classiﬁcation
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Navarro et al.39 demonstrated the causal relationship that
linked miR-135a to JAK2 downregulation and to the
consequent disruption of STAT-mediated Bcl-xL anti-
apoptotic function: low miR-135a level was signiﬁcantly
associated to higher proliferation rate and poorer out-
come. Similarly, low mir-135a levels had also unfavorable,
and independent, prognostic value in chronic lymphocytic
leukemia40. Due to the limited number of cases in our
series and the heterogeneous treatment received from
patients with available follow-up (19 of 30), the prognostic
signiﬁcance of this miRNA in MM remains to be fully
elucidated.
Importantly, RNA-seq analysis indicated several
moRNA species expressed in myeloma. Most of the
moRNAs stemmed from the 5’ arm of the hairpin, in close
continuity if not overlapping to the so-called “exact”
mature miRNA, in accordance with previous reports21. In
support of this, the most reliable hypothesis, to date,
suggests that moRNAs are secondary products of the
Drosha/DGCR8-mediated processing of pre-miRNA21. As
regards the validation of the obtained results, importantly,
qRT-PCR analysis revealed high correlation with RNA-
seq data, indicating the effectiveness of the detection of
both annotated and newly detected sRNAs.
Little evidence have been published on the involvement
of the offset RNA species in tumors and primarily limited
to their structural description15,20 or to the identiﬁcation
of moRNAs differentially expressed in cancer cells19. In
this regard, our report of differential moRNA expression
in myeloma subgroups, as well as of their possible tar-
geting relationships, encourages further investigation of
the possible biological roles of these moRNAs.
Fundamental contributions to the interpretation of the
moRNA functions, supporting the hypothesis that at least
some of them can be post-transcriptional regulators of
gene expression, were provided by recent studies. A ﬁrst
study on viral miRNAs and moRNAs expressed in virus-
induced tumors of rhesus macaques gave, by luciferase
reporter assay, the proof of principle that an artiﬁcial RNA
containing a perfect target site for a moRNA can be tar-
geted, and signiﬁcantly downregulated, by the moRNA,
conﬁrming that a moRNA can act as a miRNA, but
leaving open the question if actually moRNAs can effec-
tively somehow regulate gene expression15. In this regard,
two studies investigated by microarray analysis the effect
on gene expression of the enforced expression of a
moRNA. The ﬁrst one, after reporting high and selective
expression of moRNAs in embryonic stem cells, showed
Fig. 4 Validation by qRT-PCR for four sRNAs of differential expression detected by RNA-seq. Solid line: ﬁtting linear regression; dashed line: ﬁtting
lowess regression
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the gene expression modulation upon moR-103a-2-3p
transfection, supporting the hypothesis that the moRNA
acts directly as a post-transcriptional regulator21. Later, it
has been demonstrated that moR-21 inhibits cell pro-
liferation and mediates gene expression regulation in
vascular smooth muscle cells22. Beyond consistently
supporting the functionality of moRNAs, the two afore-
mentioned studies provided somewhat discordant inter-
pretations about a possible connection between moRNA
and cognate miRNA roles. In fact, moR-103a-2-3p
seemed to have functions that are not linked to the
function of miR-103a-3p. Conversely, a close connection
between miR-21 and moR-21 was outlined, showing that
gene regulation was exerted by moR-21 in competitive
way with miR-21, exploiting the presence in the target
gene of either “seed” or “seed match” regions that allow
modulation of gene expression. Overall, these ﬁndings
sustain the notion of a close functional connection
between different non-coding RNA species and prompt
for further investigation aimed at considering a compre-
hensive portrait of these sequences in MM.
In conclusion, RNA-seq of a representative panel of
MM tumors conﬁrmed and extended miRNA transcrip-
tional proﬁling data obtained by microarray, and gener-
ated a more complete overview of small non-coding RNA
in MM, unraveling also speciﬁc moRNAs that demand
further investigations and may represent, like miRNAs,
primary actors in MM biology.
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